Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic

Nicole DeFeudis

Editor

A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Haney is reeling in another $133 million for Skyhawk Therapeutics. And it sounds like he’s got the S-1 papers in his back pocket.

Skyhawk unveiled the latest round led by Fidelity Management and Research on Tuesday morning, which Haney says is likely the company’s last venture round before going public. Other big name investors like GreatPoint Ventures and Rock Springs Capital also chipped in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Sanofi restructures US commercial vaccines sales force

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Bill Haney adds an­oth­er $133M to Sky­hawk's cof­fers, as the RNA start­up guns for the clin­ic

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic